Biocon LimitedNSE: BIOCON

Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK

· Issued by Biocon Limited

Summary by 6ix AI

Biocon Ltd. said on August 18, 2026 that its U.S. subsidiary received supplemental approval from the U.S. Food and Drug Administration (FDA) for YESINTEK (ustekinumab-kfce) in a single-dose prefilled autoinjector, in 45 mg/0.5 mL and 90 mg/mL strengths.

Key details

  • YESINTEK is a biosimilar (a near-copy of an existing biologic drug) to Janssen Biotech's STELARA (ustekinumab).
  • The FDA originally approved YESINTEK on November 29, 2024, as a single-dose prefilled syringe (45 mg/0.5 mL or 90 mg/mL) and single-dose vials (45 mg/0.5 mL and 130 mg/26 mL).
  • YESINTEK is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severe Crohn's disease and ulcerative colitis in adults.
  • To date, the FDA has approved eight ustekinumab biosimilar products.

6ix AI wrote this summary from the release below and checked it against the release.

On August 18, 2026, Biocon Ltd. (“Biocon”) announced that its U.S. subsidiary has received supplemental U.S. FDA approval for YESINTEK® (ustekinumab-kfce) in a single-dose prefilled autoinjector, 45 mg/0.5 mL and 90 mg/mL. YESINTEK® was originally approved by the FDA on November 29, 2024, in 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe; 45 mg/0.5 mL solution in a single-dose vial; and 130 mg/26 mL solution in a single-dose vial.

YESINTEK®, biosimilar to Janssen Biotech's STELARA® (ustekinumab), is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severe Crohn's disease and ulcerative colitis in adults. To date, the FDA has approved eight ustekinumab biosimilar products.

Allegra J. Padula
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York
NY 10018
UNITED STATES
Tel: 212813 8800
E-mail: [email protected]
URL: www.goodwinlaw.com

© Mondaq Ltd, 2026 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Biocon Limited on 6ix

Story so far

Earlier from Biocon

Later from Biocon

All Biocon news releases